|本期目录/Table of Contents|

[1]郭君君,刘婧,张素洁,等.磷酸二酯酶-9A对评估冠状动脉粥样硬化病变程度的临床价值[J].国际心血管病杂志,2017,03:181-184.
　GUO Junjun,LIU Jing,ZHANG Sujie,et al.Clinical value of phosphodiesterase-9A in evaluation of the degree of coronary atherosclerosis[J].International Journal of Cardiovascular Disease,2017,03:181-184.
点击复制

磷酸二酯酶-9A对评估冠状动脉粥样硬化病变程度的临床价值(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2017年03期
页码:
181-184
栏目:
临床研究
出版日期:
2017-05-30

文章信息/Info

Title:
Clinical value of phosphodiesterase-9A in evaluation of the degree of coronary atherosclerosis
作者:
郭君君; 刘婧; 张素洁; 黄俊逸; 曹阳; 郑宏超
200444 上海大学生命科学学院(郭君君,刘 婧, 张素洁,黄俊逸); 200031 上海市徐汇区中心医院心内科(曹 阳,郑宏超)
Author(s):
GUO Junjun1;  LIU Jing1;  ZHANG Sujie1;  HUANG Junyi1;  CAO Yang2;  ZHENG Hongchao2
1. School of Life Sciences of Shanghai University, Shanghai 200444; 2. Xuhui District Central Hospital, Shanghai 200031, China
关键词:
磷酸二酯酶-9A;  冠状动脉粥样硬化;  斑块
Keywords:
Phosphodiesterase-9A;  Coronary atherosclerosis;  Plaque
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2017.03.014
文献标识码:
-
摘要:
目的:探讨血浆磷酸二酯酶-9A(PDE-9A)水平与冠状动脉(冠脉)粥样硬化病变严重程度的关系。方法:选择经冠脉造影确诊的冠状动脉粥样硬化性心脏病(冠心病)75例(单支病变33例、二支病变22例、三支病变20例)和同期行冠脉造影无血管病变的对照组25例,应用ELISA法测定血浆PDE-9A水平。以冠脉病变血管支数及Gensini积分评估冠脉粥样硬化程度,并与血浆PDE-9A水平进行相关分析。应用ROC曲线评估PDE-9A对严重冠脉病变的预测价值。结果:冠心病组血浆PDE-9A水平明显高于对照组[(29.5
Abstract:
Objective:To assess the relationship between the level of phosphodiesterase-9A(PDE-9A)and the degree of coronary atherosclerosis.Methods:Plasma levels of PDE-9A were measured by enzyme linked immune sorbent assay(ELISA)in 75 patients with coronary artery

参考文献/References

[1] Burke-Gaffney A, Brooks AV, Bogle RG. Regulation of chemokine expression in atherosclerosis [J].Vascular Pharmacol, 2002, 38(5):283-292.
[2] Chen F,Eriksson P,Kimura T,et al.Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque [J].Coron Artery Dis, 2005, 16(3):191-197.
[3] Lugnier C. Cyclic nucleotide phosphodiesterase(PDE)superfarmily:A new target for the development of specific therapeutic agents[J].Pharmacol Ther, 2006, 109(3):366-398.
[4] Conti M, Jin SL.The molecular biology of cyclic nucleotide phosphordiesterases[J]. Prog Nucletic Acid Res Mol Biol, 1999, 63(1):1-38.
[5] Heckman PR, Wouters C, Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer’s disease: a translational overview [J]. Curr Pharm Des, 2015, 21(3):317-331.
[6] Lee DI, Zhu G, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease[J].Nature, 2015, 519(7544):472-476.
[7] Turan B, Erkol A, Mutlu A, et al. Effectiveness of left Judkins catheter as a single multipurpose catheter in transradial coronary angiography from right radial artery: A randomized comparison with conventional two-catheter strategy[J]. J Interv Cardiol, 2016, 29(3):257-264.
[8] Gensini GG. A more meaningful scoring system for determming the severity of coronary heart disease[J].Am J Cardiol, 1983, 51(3):606-608.
[9] Yanai S, Toyohara J, Ishiwata K, et al. Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8(SAMP8)through a dual effect on cAMP and blood-brain barrier[J].Neuropharmacology, 2016, 116:247-259.
[10] Kim T, Folcher M, Charpin-EI Hamri G, et al. A synthetic cGMP-sensitive gene switch providing Viagra(○R)-controlled gene expression in mammalian cells and mice[J].Metab Eng,2015, 29:169-179.
[11] Massimi M, Cardarelli S, Galli F, et al.Increase of intracellular cyclic AMP by PDE4 inhibitors affects HepG2 cell cycle progression and survival[J]. J Cell Biochem, 2017, 118(6):1401-1411.

备注/Memo

备注/Memo:
基金项目:新一轮上海医学重点专科建设计划(ZK2012A39)
通信作者:郑宏超,Email:zhenghchao@126.com
更新日期/Last Update: 2017-05-30